Hopes that Onxeo SA's doxorubicin-loaded nanoparticle, Livatag, would finish a pivotal trial and be ready for filing as a new treatment for challenging cases of hepatocellular carcinoma were dashed as the drug failed to outperform standard-of-care therapies, such as oxaliplatin, gemcitabine or tyrosine kinase inhibitors. News of the results sent Onxeo shares (PARIS:ONXEO) down more than 50 percent and turned the company's attentions to finding a partner to advance Livatag, as it focuses on other programs in its pipeline.